Please assess the completion status of the following clinical trial:

Trial Title: Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. For registration: Willing to undergo allogeneic transplantation.~2. For registration: Age equal to or less than 65 years old.~3. For registration: Metastatic RCC with predominant conventional cell type.~4. For registration: Prior nephrectomy.~5. For registration: Stage IV RCC. If patient has prior single brain metastasis treated with complete surgical resection or stereotactic radiation therapy, no recurrence or brain edema from the end of treatment for at least 6 months has to be shown by radiological imaging.~6. For registration: Zubrod performance status \< one.~7. For registration: Potential related donor for allogeneic stem cell transplantation.~8. For registration: At least one prior treatment for metastatic RCC. Radiation therapy or surgery is not counted as a treatment.~9. For registration: Signed an informed consent.~10. For transplantation: Zubrod performance status \< one.~11. For transplantation: An HLA-matched (defined as 6/6 matches) related donor.~12. For transplantation: Failed at least one prior treatment for metastatic RCC. Radiation therapy or surgery is not counted as a treatment.~13. For transplantation: Adequate major organ functions (see section 4.17-4.20).~14. For transplantation: Signed an informed consent for allogeneic stem cell transplantation.~Exclusion Criteria:~1. For registration: Prior history of allogeneic stem cell transplantation.~2. For registration: Histologic feature with predominant non-conventional cell type.~3. For registration: Multiple brain metastasis.~4. For registration: Life expectancy is severely limited by concomitant illness.~5. For transplantation: Multiple brain metastasis.~6. For transplantation: Life expectancy is severely limited by concomitant illness.~7. For transplantation: Clinically significant active infections.~8. For transplantation: HIV infection.~9. For transplantation: Chronic active hepatitis~10. For transplantation: Pregnant or lactating women.~11. For transplantation: Has all three risk factors: high serum lactate dehydrogenase, low hemoglobin, high corrected serum calcium.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine + Cyclophosphamide with ASCT (Type: EXPERIMENTAL): ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
- Fludarabine + Melphalan with ASCT (Type: EXPERIMENTAL): ASCT=Allogeneic Hematopoietic Stem Cell Transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).